(Adnkronos) - "La novità più importante, secondo me, da un punto di vista del paziente con mieloma multiplo è che selinexor è una terapia orale che quindi permette alla persona di non dover essere in ospedale per poterla ricevere”. Sono le parole di Felice Bombaci, coordinatore nazionale gruppi pazienti Ail - Associazione italiana contro leucemie, linfomi e mieloma, a margine della conferenza stampa organizzata a Milano da Menarini Stemline Italia per discutere le nuove prospettive nella cura per il mieloma multiplo e la neoplasia a cellule dendritiche plasmacitoidi blastiche.
Category
🗞
NewsTranscript
00:00The main difficulty for the patients is to get to the diagnosis of multiple myeloma,
00:10because often for people who are affected, getting to the diagnosis is not such a
00:15obvious thing. It is not the hematologist, the first specialist they turn to, but often
00:20it is the family doctor and the orthopedic doctor, in 80% of cases it is so.
00:25So this is the main obstacle. Then the difficulties are to overcome the first
00:33moments of pain, of problems and then understand that the therapies are working
00:40and then go back to your normal life.
00:45For myeloma there is a new class of drugs available, so a scenario opens up
00:50to improve the equipment that doctors have available to treat the disease.
00:58But the most important thing, in my opinion, from a patient's point of view, is that
01:02this therapy is an oral therapy, a therapy that therefore allows the person not to have
01:07to be in the hospital to be able to receive it in administration.
01:11This also frees the caregiver from the need to accompany the person in the hospital,
01:17thus bringing a better quality of life and not the reduction of work, which instead
01:23in 38% of cases, we know from an investigation that we have carried out, is the main problem
01:28also for caregivers who have to reduce or even leave work to support the loved one.